Spectrum Pharmaceuticals

Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operation. The Company and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Company Growth (employees)
Type
Public
HQ
Henderson, US
Founded
2002
Size (employees)
227 (est)+8%
Website
sppirx.com
Spectrum Pharmaceuticals was founded in 2002 and is headquartered in Henderson, US

Spectrum Pharmaceuticals Office Locations

Spectrum Pharmaceuticals has an office in Henderson
Henderson, US (HQ)
240 11500 S Eastern Ave

Spectrum Pharmaceuticals Data and Metrics

Spectrum Pharmaceuticals Financial Metrics

Spectrum Pharmaceuticals's revenue was reported to be $29.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

29.1 m

Gross profit (Q1, 2017)

21 m

Gross profit margin (Q1, 2017), %

72%

Net income (Q1, 2017)

(23 m)

EBIT (Q1, 2017)

(21.3 m)

Market capitalization (17-Aug-2017)

742.5 m

Cash (31-Mar-2017)

137.2 m
Spectrum Pharmaceuticals's current market capitalization is $742.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

143.5 m186.5 m136.9 m146.4 m

Revenue growth, %

30%(27%)7%

Cost of goods sold

28.6 m27 m27.7 m28 m

Gross profit

114.9 m159.5 m109.2 m118.5 m

Gross profit Margin, %

80%86%80%81%

Operating expense total

194.6 m218.4 m203.3 m208.1 m

EBIT

(38.8 m)(31.6 m)(40.7 m)(61.6 m)

EBIT margin, %

(27%)(17%)(30%)(42%)

Interest expense

(2.2 m)(8.6 m)(9.1 m)(9.4 m)

Interest income

(2.2 m)(8.6 m)(9.1 m)(9.4 m)

Pre tax profit

(36.6 m)(43.5 m)(50.4 m)(70.8 m)

Income tax expense

(25.5 m)(2.2 m)(406 k)

Net Income

(62.1 m)(45.7 m)(50.8 m)(68.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

46.9 m48 m38.6 m45 m28.6 m43.9 m33.9 m33.4 m29.1 m

Cost of goods sold

6.2 m6.5 m7.1 m6 m8.4 m5.6 m5.6 m7.5 m8.1 m

Gross profit

40.7 m41.5 m31.5 m39 m20.2 m38.3 m28.3 m25.9 m21 m

Gross profit Margin, %

87%86%82%87%70%87%83%78%72%

R&D expense

11.3 m14.4 m15.9 m9.6 m9.9 m15.5 m14.3 m13.3 m14.7 m

General and administrative expense

25.4 m24.1 m23.3 m22.6 m19.4 m22 m27.6 m19.5 m18.6 m

Operating expense total

36.7 m38.5 m39.2 m32.1 m29.3 m37.4 m41.9 m32.8 m33.3 m

EBIT

(1.4 m)(4.1 m)(21.7 m)(34 k)(16.1 m)(6.3 m)(22.1 m)(16 m)(21.3 m)

EBIT margin, %

(3%)(9%)(56%)(0%)(56%)(14%)(65%)(48%)(73%)

Interest expense

(2 m)(2.4 m)(2.2 m)(2.3 m)(2.3 m)(2.3 m)(2.4 m)(2.4 m)(2.1 m)

Pre tax profit

(4.9 m)(8.1 m)(25.4 m)(2.4 m)(18.8 m)(9.4 m)(24.4 m)(17.9 m)(23.2 m)

Income tax expense

1.3 m(3.5 m)(138 k)201 k

Net Income

(3.6 m)(11.5 m)(25.6 m)(2.3 m)(18.7 m)(9.3 m)(24.3 m)(17.5 m)(23 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

156.3 m129.9 m139.7 m158.2 m

Accounts Receivable

7.5 m5.5 m12.6 m5.8 m

Inventories

13.5 m9.2 m4.2 m8.7 m

Current Assets

235.2 m222.5 m191.3 m216.7 m

PP&E

1.5 m1.4 m918 k449 k

Goodwill

18.5 m18.2 m18 m17.9 m

Total Assets

499.2 m490 m421.2 m428.8 m

Accounts Payable

61.1 k

Current Liabilities

90 m109.4 m76.3 m65.5 m

Total Liabilities

192.7 m

Preferred Stock

123 k

Additional Paid-in Capital

518.1 m538.6 m552.1 m640.2 m

Retained Earnings

(237.6 m)(283.3 m)(334.1 m)(402.6 m)

Total Equity

281.6 m254.6 m212.9 m236 m

Financial Leverage

1.8 x1.9 x2 x1.8 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

132.4 m144.2 m123.4 m142.3 m136.5 m132.3 m155.8 m171.6 m137.2 m

Accounts Receivable

11.8 m9.3 m7.9 m8.2 m13.5 m15.2 m7 m7.1 m5.9 m

Inventories

10.9 m9.9 m9.1 m8.8 m7.1 m3.2 m6.4 m7.3 m10.4 m

Current Assets

220.1 m231.6 m216 m207.2 m209.5 m172.5 m206.7 m231.4 m197 m

PP&E

1.4 m1.4 m1.3 m1.3 m1.1 m810 k643 k538 k493 k

Goodwill

18.5 m18.3 m17.9 m18 m18 m18 m18 m18 m17.9 m

Total Assets

474.9 m509.7 m468.6 m454.3 m447.7 m401.4 m429.2 m449.4 m403.5 m

Current Liabilities

77.5 m112.9 m109.8 m90.5 m102.3 m59.5 m58.3 m62.3 m57.2 m

Additional Paid-in Capital

532.6 m535.6 m541.2 m545.4 m548.2 m555.1 m606.2 m638 m642.5 m

Retained Earnings

(268.8 m)(280.4 m)(308.9 m)(311.2 m)(330 m)(343.4 m)(367.7 m)(385.2 m)(425.6 m)

Total Equity

265.7 m256.6 m234.1 m214.7 m208.3 m235.9 m250.8 m217.4 m

Financial Leverage

1.8 x2 x1.9 x2.1 x1.9 x1.8 x1.8 x1.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.1 m)(45.7 m)(50.8 m)(68.5 m)

Depreciation and Amortization

22.1 m25.4 m31.9 m26.5 m

Accounts Receivable

42.6 m(22 m)40.2 m(9.5 m)

Inventories

1.6 m4.3 m1.9 m(5.8 m)

Cash From Operating Activities

(2.1 m)(3.6 m)6.7 m(40.5 m)

Purchases of PP&E

(161 k)(934 k)(223 k)(78 k)

Cash From Investing Activities

(14.3 m)(21.8 m)2.8 m(679 k)

Cash From Financing Activities

35.3 m812 k1.5 m59.6 m

Interest Paid

1.2 m3.2 m3.3 m3.3 m

Income Taxes Paid

329 k335 k11 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.6 m)(11.5 m)(25.6 m)(2.3 m)(18.7 m)(9.3 m)(24.3 m)(17.5 m)(23 m)

Accounts Receivable

11.8 m9.3 m7.9 m8.2 m13.5 m15.2 m7 m7.1 m5.9 m

Inventories

10.9 m9.9 m9.1 m8.8 m7.1 m3.2 m6.4 m7.3 m10.4 m
USDY, 2017

Revenue/Employee

132.6 k

Financial Leverage

1.9 x

Spectrum Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials

3

Phase II Trials

1

Phase III Trials

3

Spectrum Pharmaceuticals Market Value History

Traffic Overview of Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Company Life and Culture

You may also be interested in